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Abstract
Background: Platelet-derived growth factor D (PDGF-D) plays an important role in angiogenesis, vessel
remodeling, inflammation and repair in response to injury. We hypothesized that genetic variation in PDGFD gene
might alter the susceptibility to stroke.
Findings: We determined the genotypes of a single nucleotide polymorphism (SNP) (-858A/C, rs3809021) in 1484
patients with stroke (654 cerebral thrombosis, 419 lacunar infarction, 411 intracerebral hemorrhage [ICH]) and 1528
control subjects from an unrelated Chinese Han population and followed the stroke patients up for a median of
4.5 years.
The -858AA genotype showed significantly increased risk of ICH (dominant model: odds ratio [OR] 1.29, 95%
confidence interval [CI] 1.00-1.68, P = 0.05; additive model: OR 1.24, 95% CI 1.01-1.52, P = 0.04) than wild-type
genotype. Further analyses showed that -858AA genotype conferred about 2-fold increase in risk of non-
hypertensive ICH (dominant model: OR 2.1, 95%CI 1.34-3.29, P = 0.001; additive model: OR 1.75, 95% CI 1.24-2.46, P
= 0.001). After a median follow-up of 4.5 years, -858AA genotype was associated with a reduced risk of ICH
recurrence (dominant model: adjusted hazard ratio [HR] 0.09, 95%CI 0.01-0.74, P = 0.025; additive model: HR 0.21,
95% CI 0.04-1.16, P = 0.073) in non-hypertensive patients.
Conclusions: The -858AA genotype is probably associated with risk for non-hypertensive ICH. Further studies
should be conducted to reveal the role of PDGF-D at various stages of ICH development–beneficial, or deleterious.
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Introduction
Stroke is a leading cause of death and disability in China
[1]. The number of patients who die from stroke is
more than three times that from coronary heart disease
in China; in contrast coronary heart disease-related
mortality is 2 to 3 times greater than the stroke-related
mortality in Western nations [2,3]. Each year, 1.5 to 2
million people have a first-ever stroke, and more than
o n em i l l i o nd i ef r o ms t r o k e - r e l a t e dc a u s e si nC h i n a
[4-6]. Among all subtypes of stroke, intracerebral
hemorrhage (ICH) accounts for 10 to 15 percent of
strokes in most western populations, whereas up to 55%
of strokes in the Chinese population are ICH [7,8]. The
reasons for the high incidence of stroke, especially the
hemorrhagic subtype, among the Chinese population,
remain unknown.
Hypertension is the most important cause for sponta-
neous, non-traumatic ICH both in western nations and
in Chinese population [9,10]. However, non-hyperten-
sive intracerebral hemorrhages, which may have differ-
ent pathologies, mechanisms and genetic background
from hypertensive ICH, are not rare. Given that there
are limited modifiable risk factors for ICH and few pro-
ven preventative therapies other than control of hyper-
tension, the most promising route to prevention and
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iants with a role in ICH [11]. Identification of genetic
polymorphisms associated with hypertensive and non-
hypertensive ICH would facilitate risk stratification as
well as illuminate the underlying biology.
Platelet-derived growth factor D (PDGF-D) is the most
recently discovered member of the PDGF family and sig-
nals mainly through PDGF receptor-b (PDGFR-b) [12].
PDGF-D has been observed to stimulate expression of
MMP-2 and MMP-9 in vascular smooth muscle cells
(SMCs) and degradation of vascular basement membrane,
which may lead to a loss of vessel wall integrity [13]. It has
also been reported to be important in the processes of
inflammation, angiogenesis and vessel remodeling in
response to injury [14,15]. We therefore hypothesized that
alternations in promoter region of PDGF-D gene might be
associated with ICH. To test this hypothesis, we investi-
gated the association of genetic variants in PDGFD with
the risk of first-ever ICH in a large case-control stroke
study in China. We also prospectively followed patients
with primary ICH for a median 4.5 years and assessed the
relationships of PDGFD variants to the risk of recurrence.
Methods
The study was approved by both the ethics committee
of FuWai Hospital and the local ethics committees of
collaborative hospitals. All participants reported them-
selves to be of Han nationality and provided written
informed consent.
Study population
This is a multicenter study for assessment of risk factors
of stroke sponsored by the Ministry of Science and
Technology of China (973 Project). Initially, 2000
patients with stroke and 2000 control subjects were
recruited as described previously [10,16].
Stroke was defined as a sudden onset of nonconvulsive
and focal neurological deficit persisting for > 24 hours.
Cerebral thrombosis was diagnosed if the patient had
the characteristics of cerebral cortical dysfunction, and
CT scan or MRI performed within 28 days of onset
either showed an area of low attenuation in a region
compatible with the clinical symptoms or failed to iden-
tify an alternative cause of the symptoms. For CT/MRI
readers, the intrareader variability was not calculated.
Among all subtypes of hemorrhagic stroke, only sponta-
neous, non-traumatic, primary ICH was in the range of
selection. Other types of stroke, including transient
ischemic attack, subarachnoid hemorrhage, embolic
brain infarction, brain tumors, and cerebrovascular mal-
formation, and severe systemic diseases such as collage-
nosis, endocrine and metabolic disease (except diabetes
mellitus [DM]), inflammation, liver, neoplastic, or renal
diseases were in the range of exclusion.
Before data analysis, 516 stroke cases and 472 controls
were excluded for indefinite diagnosis (24 cases),
absence of plasma (76 cases and 93 controls), insuffi-
cient DNA (355 cases and 309 controls), and failure of
genotyping (61cases and 70controls). No significant dif-
ferences were found in clinical characteristics between
the included and excluded subjects. Finally, 1484
patients (654 cerebral thrombosis, 419 lacunar infarc-
tion, 411 ICH) and 1528 controls were eligible for
genetic analysis.
Follow-up and Outcome Assessment
To assess whether genetic variations contributed to the
risk of ICH recurrence after the first-ever ICH, we pro-
spectively followed this stroke population through May
31, 2006 by a standard questionnaire and telephone con-
tact by physician investigators. During a median 4.5
years (range, 0.1 to 5.4 years) of follow-up for 411
patients with ICH, 14 participants were lost and
excluded from analysis. Follow-up data were completed
for 397 stroke patients (302 hypertensive and 95 non-
hypertensive, follow-up rate 96.5%).
Biochemical Variable Determination and Clinical Data
Collection
Blood samples were obtained after at least a 12-hour
overnight fasting period and pre-chilled vacutainers and
immediately centrifuged. The biochemical variable
determination and clinical data collection were per-
formed as described previously [10,16].
DNA isolation, genetic variant selection and genotyping
DNA was extracted from the buffy coat fraction of cen-
trifuged blood using the QIAmp Blood Kit (Qiagen,
Chatsworth, CA). The PDGF-D gene is located on chro-
mosome 11q22.3 [12]. The selection of genetic variants
was based on the HapMap CHB sample using the pair-
wise option of the Haploview version of Tagger pro-
gram. A minimum r
2 of 0.8 was chosen as a threshold
for all analyses. Only one Tagger SNP (rs3809021,
-858A/C) with a minor allele frequency more than 5%
was genotyped within the promoter region of PDGFD
[17]. Sequence inspection and database searches have
indicated that the single-base substitution at -858 site
could affect DNA binding of several transcription fac-
tors, including Ap-1, c-Jun, c-Fos and Sp1-like factors,
made this variant our prime candidate.
Detailed descriptions of genotyping were shown in
[Additional file 1].
Luciferase reporter assays
We investigated whether the variant at position -858
affects the transcriptional activity of the PDGFD promo-
ter (from -1168 to +185) in HCT-116 cells. The detailed
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in [Additional file 2].
Statistical Analysis
The distribution of continuous variables was tested for
normality with a one-sample Kolmogorov-Smirnov test.
Because the level of triglyceride was highly skewed, the
Mann-Whitney nonparametric method was applied to
compare the differences between patients and controls.
Continuous variables were compared by unpaired Stu-
dent t test or one-way ANOVA, and the categorical
variables were compared by chi-square test.
Hardy-Weinberg equilibrium of each variant was
tested using chi-square test. Odds ratios (ORs) and 95%
confidence interval (CI) were used to determine the
association between genotypes and the risk of ICH.
Multivariate unconditional logistic regression was used
to estimate OR and 95% CI after adjustment for age,
gender, body mass index (BMI), hypertension, DM,
HDL cholesterol (HDL-C), Non-HDL cholesterol (non-
HDL-C), total cholesterol (TC), triglyceride (TG), drink-
ing and smoking status. Multiple testing was adjusted
using Bonferroni correction.
The Kaplan-Meier analysis and Cox proportional
hazards models were used to describe the association of
genotypes with incidence of ICH recurrence and cardio-
vascular deaths. Follow-up began on the date of diagno-
sis of the first index ICH and continued until the date
of a recurrent stroke or the end of follow-up period.
Hazard Ratio (HRs) and 95% CI were estimated using
multivariate Cox proportional hazards models after
adjustment for age, gender, BMI, hypertension, HDL-C,
TC, TG, DM, smoking status, and alcohol intake.
All reported P values are 2-sided, and P < 0.05 is con-
sidered statistically significant. Analyses were performed
with SPSS software version 11.0 (SPSS Inc, Chicago),
and Stata software version 9.0 (Stata Corp, College Sta-
tion, Tex). The power analysis was performed with the
software Quanto (http://hydra.usc.edu/gxe/).
Results
Characteristics of the Subjects
Proportions from each of the clinical sites for cases and
controls were shown in [Additional file 3]. The demo-
graphic and clinical characteristics of the subjects in the
present study are shown in Table 1. ICH patients had a
higher prevalence of conventional vascular risk factors,
including higher in blood pressure, fasting blood glu-
cose, cigarette smoking, lower in HDL-C, TC and non-
HDL-C.
The present study had > 80% power to detect an asso-
ciation with ORs of ≥ 1.2 for alleles at 10% to 40% fre-
quency for the total population and the subgroup
analysis.
PDGFD -858 variant was associated with risk of first-ever
ICH
The distribution of PDGFD genotypes of -858 is shown in
Table 2, and fulfilled expectations of Hardy-Weinberg
equilibrium in both cases and controls. Genotype (CC-
AC-AA) analyses were conducted for dominant model
(AC+AA vs. CC), additive model (CC vs.A Cvs. AA) and
recessive model (CC+AC vs.A A ) .T h ea d d i t i v eg e n e t i c
model assumes that there is a linear gradient in risk
between the CC, AC and AA genotypes (CC genotype
baseline). After adjustment for age, gender, BMI, smoking,
HDL, non-HDL-C, TC, TG, blood pressure and fasting
blood glucose with multivariate logistic regression analysis,
the presence of the AA genotype of the -858 locus showed
significantly increased risk of ICH (dominant model: odds
ratio [OR] 1.29, 95% confidence interval [CI] 1.00-1.68, P
= 0.05; additive model: OR 1.24, 95% CI 1.01-1.52, P =
Table 1 Clinical characteristics of cases and control subjects
Characteristics Control Subjects Thrombosis Stroke Lacunar Stroke ICH
n 1528 654 419 411
Age, yrs 60.1(8.5) 61.4(9.8)** 61.1(8.3)** 58.4(9.5)**
Male gender, % 60.2 62.7 62.6 62.7
BMI, kg/m
2 24.2(3.4) 24.4(3.6)* 24.5(3.1)* 24.1(3.6)
HDL-C, mmol/L 1.06(0.31) 0.88(0.26)** 0.93(0.27)** 0.90(0.31)**
Non-HDL-C, mmol/L 3.94(0.96) 3.97(1.02) 3.83(0.94) 3.64(0.94)**
TC, mmol/L 4.99(0.99) 4.86(1.04)* 4.77(0.95)** 4.55(1.00)**
TG, mmol/L 1.47(13.5) 1.73(8.41)** 1.72(12.9)** 1.48(13.7)
Smoking, % 38.4 45.6* 46.7* 47.9*
Drinking, % 32.5 40.2** 41.7** 42.1**
Hypertension history, % 28.9 63.6** 64.1** 76.3**
DM history, % 6.2 16.4 12.1 7.3
Age, body mass index (BMI), high-density lipoprotein cholesterol (HDL-C), non-HDL-C, total plasma cholesterol (TC), are given as mean (standard deviation);
triglycerides (TG) values as median (range); and other values as number of individuals (n) with percentage (n/N) in parentheses.
*p < 0.05 versus control group; **p < 0.01 versus control group.
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than wild-type genotype.
Of the 411 ICH cases recruited for this study, 314
were hypertensive (with hypertension history) ICH and
97 were non-hypertensive. Further analyses showed that
-858AA genotype conferred about 2-fold increase in risk
of non-hypertensive ICH (dominant model: OR 2.1, 95%
CI 1.34-3.29, P = 0.001; additive model: OR 1.75, 95%
CI 1.24-2.46, P = 0.001; recessive model: OR 1.77, 95%
CI 0.79-3.95, P = 0.17) (Table 3). No association was
observed between the PDGFD variant and hypertensive
ICH and atherothrombotic stroke. After correction for
multiple testing by Bonferroni procedure, the association
of -858AA genotype with the risk of non-hypertensive
ICH remained statistically significant.
PDGFD -858 variant and risk of recurrent ICH
During a median 4.5 years (range, 0.1 to 5.4 years) of
follow-up for 397 patients, a recurrent ICH occurred in
52 persons (13.1% of all index ICH), of which 39 were
baseline hypertensive cases and 13 were baseline non-
hypertensive. The risk time for recurrence in hyperten-
sive and non-hypertensive ICH were shown in more
detail [see Additional file 4]
Among patients with non-hypertensive ICH, the var-
iant -858AA genotype was significantly associated with
reduced risk of ICH recurrence (Figure 1), which was in
contrast to its association with first-ever ICH. After
adjusting for conventional cardiovascular risk factors, we
found that -858AA genotype was associated with a
reduced risk of ICH recurrence (dominant model:
adjusted hazard ratio [HR] 0.09, 95%CI 0.01-0.74, P =
0.025; additive model: HR 0.21, 95% CI 0.04-1.16, P =
0.073; recessive model: HR 1.62, 95% CI 0.17-15.1, P =
0.671) in non-hypertensive patients. No association of
PDGFD -858 variant with ICH recurrence was found in
hypertensive patients.
Table 2 Associations of PDGFD -858A/C genotype with stroke
Genotype, n (%) Adjusted ORs Adjusted
Groups CC AC AA Models (95% CI) P Value
Controls (n = 1528) 868 (56.8) 564 (36.9) 96(6.3) 1.00
Cases (n = 1484) 775 (52.2) 595 (40.1) 114(7.7) Additive 1.15 (1.01-1.32) 0.04
Dominant 1.18 (0.99-1.39) 0.06
Recessive 1.25 (0.90-1.74) 0.18
Thrombosis (n = 654) 342 (52.3) 261 (39.9) 51 (7.8) Additive 1.13 (0.95-1.35) 0.15
Dominant 1.14 (0.91-1.42) 0.23
Recessive 1.28 (0.85-1.93) 0.25
Lacunar (n = 419) 228 (54.4) 159(38.0) 32 (7.6) Additive 1.05 (0.86-1.27) 0.63
Dominant 1.03 (0.81-1.31) 0.82
Recessive 1.19(0.75-1.90) 0.46
ICH (n = 411) 205 (49.9) 175 (42.6) 31 (7.5) Additive 1.24 (1.01-1.52) 0.04
Dominant 1.29 (1.00-1.68) 0.05
Recessive 1.44 (0.92-2.25) 0.107
Adjusted OR was obtained on multivariate logistic regression after controlling for age, gender, BMI, smoking, HDL-C, non-HDL-C, TC, TG, fasting plasma glucose,
and hypertension. Additive model: CC vs.A Cvs.AA; Dominant model: CCvs. AC/AA; Recessive model: CC/AC vs. AA.
Table 3 Associations of PDGFD -858A/C genotype with hypertensive and non-hypertensive ICH
Genotype, n (%) Adjusted ORs Adjusted
Groups CC AC AA Models (95% CI) P Value
Hypertensive ICH
Controls (n = 445) 239 (53.7) 176 (39.5) 30 (6.8) 1.00
Cases (n = 314) 165 (52.5) 126 (40.1) 23 (7.4) Additive 1.01 (0.78-1.31) 0.96
Dominant 0.94 (0.68-1.31) 0.73
Recessive 1.15 (0.62-2.15) 0.65
Non-hypertensive ICH
Controls (n = 1083) 629 (58.1) 388 (35.8) 66 (6.1) 1.00
Cases (n = 97) 39 (40.2) 50 (51.5) 8 (8.3) Additive 1.75 (1.24-2.46) 0.001
Dominant 2.10 (1.34-3.29) 0.001
Recessive 1.77 (0.79-3.95) 0.17
Adjusted OR was obtained on multivariate logistic regression after controlling for age, gender, BMI, smoking, HDL-C, non-HDL-C, TC, TG, fasting plasma glucose,
and hypertension. Additive model: CC vs.A Cvs.AA; Dominant model: CCvs. AC/AA; Recessive model: CC/AC vs. AA.
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We investigated whether the polymorphism at position
-858 affects the transcriptional activity of the PDGFD
promoter in HCT-116 cells. The variant-858A-bearing
PDGFD promoter exhibited a 3.78-fold increase in tran-
scription activity than the variant-858C-bearing promo-
ter. The pGL-3 empty vector had a negligible amount of
the luciferase activity (Figure 2). The results supported
that allele A has higher transcription activity than allele
C.
Discussion
The present study is the first clinical investigation of the
significance of PDGF-D regarding the incidence and
prognosis of ICH in a Chinese population. A common
functional variation in the promoter region of PDGFD
gene was found to be associated with more than 2-fold
Figure 1 ICH Recurrence Rate in Patients with non-
hypertensive First-ever ICH by PDGFD Variant -858A/C
Genotypes*. *Kaplan-Meier curves for ICH recurrence by PDGFD
-858A/C genotype among patients with non-hypertensive First-ever
ICH. PDGFD = Platelet-derived growth factor D. ICH = intracerebral
hemorrhage
Figure 2 SNP -858A-Bearing PDGFD Promoter Had Higher Transcription Activity. The pGL3 luciferase reporter contained either the allele A
(pGL3-A) or allele C (pGL3-C) at the promoter -858 locus. Values represent the average of 6 experiments and the bars represent the standard
deviation. The pGL3-basic was used as a negative control without any promoter sequence, and pGL3-control as a positive control. PDGFD =
Platelet-derived growth factor D.SNP = single nucleotide polymorphism; ICH = intracerebral hemorrhage
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cases, while reduced incidence of recurrent ICH.
In a small sample of south China, Han et al. have
found that the G allele of rs7950273 of the PDGFD is
associated with higher risk of ischemic stroke. However,
the associations of PDGFD variants with other type of
stroke, especially ICH have not been investigated [18].
In the present study, we found that the -858A/C varia-
tion in the PDGFD promoter region could lead to an
enhancement of PDGFD promoter activity and conse-
quently up-regulation of the expression of the gene.
Interestingly, this functional variant was only associated
with non-hypertensive cases, indicating that there are
significant differences in genetic background, mechan-
isms and pathologies between the hypertensive and non-
hypertensive ICH.
In this study, the relations between PDGFD variation
and recurrent ICH were quite contrary to the contribu-
tion of the variant to the risk of first-ever ICH, which
can probably be explained by the angiogenic and wound
healing effects of PDGF-D. PDGF-D induces macro-
phage recruitment, extracellular matrix deposition, and
blood vessel maturation, which are all part of process of
angiogenesis and wound healing [15,19]. In addition,
PDGFD is capable of inhibiting vascular leakage asso-
ciated with growth factor-induced angiogenesis. This
effect may be attributed to the PDGFD-induced stimula-
tion of the proliferation and migration of SMCs, indicat-
ing that PDGFD is capable of stabilizing newly formed
vessels through their effects on the SMCs [20].
Therefore, one can speculate that the enhancement of
PDGF-D function is associated with proliferation and
migration of SMCs, deposition of extracellular matrix,
and degradation of vascular basement membrane, which
on one hand lead to a loss of vessel wall integrity,
resulting in increased susceptibility to primary non-
hypertensive ICH. On the other hand, the above pro-
cesses are also important procedures for angiogenesis
and are essential for the development of neovessels dur-
ing the restoration of vasculature system of injured
brain after primary ICH [21,22].
The present study has limitations. First, although the
sample size of this study is large, the relatively small
number of each stroke subtype, especially the small
sample size of non-hypertensive ICH, is a limitation of
the present study; therefore further large scale studies
focused on non-hypertensive ICH will be needed. Sec-
ond, multiple testing of the genetic associations must be
noted. After Bonferroni correction for multiple testing,
the only association that maintains is the association
with non-hypertensive ICH. Third, for CT/MRI readers,
the intrareader variability was not calculated. However,
the confirmed diagnosis of each case was based on
results of at least two CT/MRI readers and one
neurologist; disparities were resolved by discussion. The
accuracy of the diagnosis was guaranteed by these
methods.
In conclusion, our observations suggest that PDGFD
-858A/C variant is probably associated with risk for
non-hypertensive ICH. Further studies should be con-
ducted to reveal the role of PDGF-D at various stages of
ICH development–beneficial, or deleterious.
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